thiazoles has been researched along with roflumilast in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Arban, R; Cavallini, P; Davies, CH; Davis, TG; Gray, FA; Montanari, D; Negri, M; Poffe, A; Rutter, AR; Schneck, J; Vicentini, E; Wren, PB | 1 |
| Song, SD; Tang, HF | 1 |
| Fortescue, R; Janjua, S; Poole, P | 1 |
2 review(s) available for thiazoles and roflumilast
| Article | Year |
|---|---|
[Progress in PDE4 targeted therapy for inflammatory diseases].
Topics: Aminopyridines; Aminoquinolines; Arthritis; Asthma; Benzamides; Cyclopropanes; Dermatitis; Humans; Inflammation; Inflammatory Bowel Diseases; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Sulfones; Thalidomide; Thiazoles | 2014 |
Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Topics: Administration, Oral; Aminopyridines; Benzamides; Cyclohexanecarboxylic Acids; Cyclopropanes; Diarrhea; Disease Progression; Forced Expiratory Volume; Humans; Middle Aged; Nitriles; Peak Expiratory Flow Rate; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic; Thiazoles; Vital Capacity | 2020 |
2 other study(ies) available for thiazoles and roflumilast
| Article | Year |
|---|---|
New drugs 2012 part I.
Topics: Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzazepines; Benzimidazoles; Benzofurans; Ceftaroline; Cephalosporins; Cyclopropanes; Drug Approval; Drug Combinations; Humans; Imidazoles; Indoles; Isoindoles; Linagliptin; Lurasidone Hydrochloride; Macrolides; Oxadiazoles; Piperazines; Proline; Purines; Quinazolines; Thiazoles; United States; Vilazodone Hydrochloride | 2012 |
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Topics: Aminopyridines; Animals; Anti-Anxiety Agents; Behavior, Animal; Benzamides; Callithrix; Cerebral Cortex; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Drug Evaluation, Preclinical; Ferrets; Inflammation; Isoenzymes; Macaca fascicularis; Male; Nootropic Agents; Oxadiazoles; Phosphodiesterase 4 Inhibitors; Pica; Rats; Rolipram; Thiazoles | 2014 |